Source comparison
Tesamorelin Legal Status: Research vs Medical Comparison
Before selecting a tesamorelin source, understanding the compliance and quality distinctions between pharmaceutical-grade and research-grade formulations determines both legal standing and practical application suitability. The table below maps these differenc
This comparison does not assign a generated winner or score.
- Before selecting a tesamorelin source, understanding the compliance and quality distinctions between pharmaceutical-grade and research-grade formulations determines both legal standing and practical application suitability. The table below maps these differences across the dimensions that matter most for researchers and prescribers.
- FDA Approval Status
- FDA-approved NDA 022505 since 2010 for HIV-associated lipodystrophy
- Not FDA-approved; classified as research chemical
- Not FDA-approved; compounded under 503B framework
- Only Egrifta carries full FDA approval—compounded and research versions lack drug product approval but serve different legal purposes
- Intended Use
- Treatment of excess abdominal fat in HIV patients with lipodystrophy
- In vitro research, cellular assays, mechanism studies
- Patient-specific compounding when prescribed for legitimate medical use
- Intended use determines legality—research peptides become unapproved drugs if used in humans
- Manufacturing Standards
- Pharmaceutical cGMP per 21 CFR Part 211; batch-to-batch consistency required
- Chemical synthesis standards; purity verification via HPLC and mass spec
- USP <795> or <797> compounding standards; 503B registration required
- Pharmaceutical standards provide highest consistency; research-grade depends entirely on supplier QC rigor
- Typical Purity
- ≥98.5% per FDA specifications; endotoxin <0.5 EU/mg
- ≥98% via HPLC for reputable suppliers; varies by source
- Variable—depends on API source and compounding facility practices
- Purity differences of 1-2% matter less than batch consistency and endotoxin levels for cellular work
- Cost per Month (2mg daily)
- $3,000-3,600 (branded Egrifta SV)
- $180-280 for 10mg (5-day supply at 2mg/day)—approximately $1,080-1,680/month
- $800-1,200/month depending on compounding pharmacy
- Research-grade offers 60-70% cost reduction but is illegal for human therapeutic use
- Traceability
- NDC code, lot numbers, FDA batch tracking
- Batch numbers; no centralized regulatory tracking
- Pharmacy lot numbers; state board oversight, not FDA batch review
- Only FDA-approved products provide full post-market surveillance and recall infrastructure